A new cell study below, for CBD users. Seems to be everywhere these days.
"Cannabidiol (CBD), a phytocannabinoid derived from Cannabis sativa, has anti-inflammatory and anti-oxidant properties, and displays anti-proliferative activity."
Front Pharmacol. 2018 Aug 13;9:889. doi: 10.3389/fphar.2018.00889. eCollection 2018.
Cannabidiol (CBD) Is a Novel Inhibitor for Exosome and Microvesicle (EMV) Release in Cancer.
Kosgodage US1, Mould R2, Henley AB2, Nunn AV2, Guy GW3, Thomas EL2, Inal JM4, Bell JD2, Lange S5,6.
Cellular and Molecular Immunology Research Centre, School of Human Sciences, London Metropolitan University, London, United Kingdom.
Research Centre for Optimal Health, Department of Life Sciences, University of Westminster, London, United Kingdom.
GW Research, Sovereign House Vision Park, Cambridge, United Kingdom.
School of Life and Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom.
Tissue Architecture and Regeneration Research Group, Department of Biomedical Sciences, University of Westminster, London, United Kingdom.
Department of Pharmacology, University College London School of Pharmacy, London, United Kingdom.
Exosomes and microvesicles (EMV) are lipid bilayer-enclosed structures, released by cells and involved in intercellular communication through transfer of proteins and genetic material. EMV release is also associated with various pathologies, including cancer, where increased EMV release is amongst other associated with chemo-resistance and active transfer of pro-oncogenic factors. Recent studies show that EMV-inhibiting agents can sensitize cancer cells to chemotherapeutic agents and reduce cancer growth in vivo. Cannabidiol (CBD), a phytocannabinoid derived from Cannabis sativa, has anti-inflammatory and anti-oxidant properties, and displays anti-proliferative activity. Here we report a novel role for CBD as a potent inhibitor of EMV release from three cancer cell lines: prostate cancer (PC3), hepatocellular carcinoma (HEPG2) and breast adenocarcinoma (MDA-MB-231). CBD significantly reduced exosome release in all three cancer cell lines, and also significantly, albeit more variably, inhibited microvesicle release. The EMV modulating effects of CBD were found to be dose dependent (1 and 5 μM) and cancer cell type specific. Moreover, we provide evidence that this may be associated with changes in mitochondrial function, including modulation of STAT3 and prohibitin expression, and that CBD can be used to sensitize cancer cells to chemotherapy. We suggest that the known anti-cancer effects of CBD may partly be due to the regulatory effects on EMV biogenesis, and thus CBD poses as a novel and safe modulator of EMV-mediated pathological events.
cancer; cannabidiol (CBD); combinatory treatment; exosomes; inflammation; microvesicles (MVs); mitochondria; peptidylarginine deiminase (PAD)
PMID: 30150937 PMCID: PMC6099119 DOI: 10.3389/fphar.2018.00889